Citation Tools

Download PDFPDF

Original research
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

Download to a citation manager

Cite this article as:
Temesgen Z, Kelley CF, Cerasoli F, et al
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial